Glecaprevir/Pibrentasvir Real-world Study in China

Sponsor
Tongji Hospital
Study ID
NCT03941821
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Key Dates

First listed
May 8, 2019
Start date
Jun 30, 2019
Status verified
May 2019
Primary completion
Jun 30, 2021
Completion
Jun 30, 2022

Study Design

Enrollment
800 participants (estimated)

Arms

  • Arm: G/P treatment
    Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment

Primary Outcome Measure

SVR 12 [ Time Frame: 12 weeks after Glecaprevir/Pibrentasvir treatments ]

Central Contacts